The neurobiology, diagnosis, and treatment of narcolepsy

Annals of Neurology

Volumn 53, Issue 2, 2003, Pages 154-166

  Scammell, Thomas E ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 HYDROXYBUTYRIC ACID; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; HLA DQB1 ANTIGEN; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; PROTRIPTYLINE; SECRETIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; VENLAFAXINE; ZOLPIDEM;

ANAMNESIS; ANOREXIA; ANXIETY DISORDER; ARTICLE; BRAIN TUMOR; CATAPLEXY; CHOLINERGIC NERVE CELL; DIFFERENTIAL DIAGNOSIS; DORSAL RAPHE NUCLEUS; HALLUCINATION; HEAD INJURY; HEADACHE; HEREDITY; HUMAN; HYPERSOMNIA; HYPOTHALAMUS; INSOMNIA; IRRITABILITY; LOCUS CERULEUS; MULTIPLE SCLEROSIS; NARCOLEPSY; NAUSEA; NERVOUSNESS; NEUROBIOLOGY; NIEMANN PICK DISEASE; NONHUMAN; NORRIE DISEASE; POLYSOMNOGRAPHY; PRADER WILLI SYNDROME; PREOPTIC AREA; PRIORITY JOURNAL; REM SLEEP; SEDATION; SOMNOLENCE; STROKE; SWEATING; TEGMENTUM; URINE INCONTINENCE; VERTIGO; WAKEFULNESS; XEROSTOMIA;

BRAIN; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES;

EID: 0037309268     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10444     Document Type: Article

References (178)

1. von Economo C. Sleep as a problem of localization. J Nervous Mental Disord 1930;71:249-259.
2. Okun ML, Lin L, Pelin Z, et al. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002;25:27-35.
3. Silber MH, Krahn LE, Olson EJ, et al. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002;25:197-202.
4. Broughton R, Dunham W, Newman J, et al. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls. Electroencephalogr Clin Neurophysiol 1988;70:473-481.
5. Broughton R, Krupa S, Boucher B, et al. Impaired circadian waking arousal in narcolepsy-cataplexy. Sleep Res Online 1998;1:159-165.
6. Harsh J, Peszka J, Hartwig G, et al. Night-time sleep and daytime sleepiness in narcolepsy. J Sleep Res 2000;9:309-316.
7. Broughton R, Dunham W, Weisskopf M, et al. Night sleep does not predict day sleep in narcolepsy. Electroencephalogr Clin Neurophysiol 1994;91:67-70.
8. Aldrich MS. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996;46:393-401.
9. Dahlitz M, Parkes JD. Sleep paralysis. Lancet 1993;341:406-407.
10. Guilleminault C, Gelb M. Clinical aspects and features of cataplexy. Adv Neurol 1995;67:65-77.
11. Anic-Labat S, Guilleminault C, Kraemer HC, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87.
12. Rubboli G, d'Orsi G, Zaniboni A, et al. A video-polygraphic analysis of the cataplectic attack. Clin Neurophysiol 2000; 111(suppl 2):S120-S128.
13. Overeem S, Lammers GJ, van Dijk JG. Weak with laughter. Lancet 1999;354:838.
14. Lammers GJ, Overeem S, Tijssen MA, et al. Effects of startle and laughter in cataplectic subjects: a neurophysiological study between attacks. Clin Neurophysiol 2000;111:1276-1281.
15. Siegel JM, Nienhuis R, Fahringer HM, et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science 1991;252:1315-1318.
16. Littner M, Johnson SF, McCall WV, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24:451-466.
17. Mayer G, Meier-Ewert K. Motor dyscontrol in sleep of narcoleptic patients (a lifelong development?). J Sleep Res 1993; 2:143-148.
18. Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992;32:3-10.
19. Carskadon MA, Dement WC, Mitler MM, et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-524.
20. Roehrs T, Roth T. Multiple Sleep Latency Test: technical aspects and normal values. J Clin Neurophysiol 1992;9:63-67.
21. Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 1993;43:55-60.
22. Mitler MM, Van den Hoed J, Carskadon MA, et al. REM sleep episodes during the Multiple Sleep Latency Test in narcoleptic patients. Electroencephalogr Clin Neurophysiol 1979; 46:479-481.
23. Chervin RD, Aldrich MS. Sleep onset REM periods during multiple sleep latency tests in patients evaluated for sleep apnea. Am J Respir Crit Care Med 2000;161:426-431.
24. Manni R, Politini L, Nobili L, et al. Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors. Clin Neurophysiol 2001;112:800-805.
25. Kandt RS, Emerson RG, Singer HS, et al. Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol 1982;12:284-288.
26. Vossler DG, Wyler AR, Wilkus RJ, et al. Cataplexy and monoamine oxidase deficiency in Norrie disease. Neurology 1996;46:1258-1261.
27. Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain 1997;120:1423-1435.
28. Schwartz WJ, Stakes JW, Hobson JA. Transient cataplexy after removal of a craniopharyngioma. Neurology 1984;34:1372-1375.
29. Aldrich MS, Naylor MW. Narcolepsy associated with lesions of the diencephalon. Neurology 1989;39:1505-1508.
30. Malik S, Boeve BF, Krahn LE, et al. Narcolepsy associated with other central nervous system disorders. Neurology 2001; 57:539-541.
31. Arii J, Kanbayashi T, Tanabe Y, et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001;56:1775-1776.
32. Scammell TE, Nishino S, Mignot E, et al. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001;56:1751-1753.
33. Clavelou P, Tournilhac M, Vidal C, et al. Narcolepsy associated with arteriovenous malformation of the diencephalon. Sleep 1995;18:202-205.
34. von Economo C. Encephalitis lethargica: its sequela and treatment. London: Oxford University Press, 1931.
35. Stiefler G. Narkolepsie nach Enzephalitis Lethargica. Wien Klin 1924;37:1044-1046.
36. Adie J. Idiopathic narcolepsy: a disease sui generis, with remarks on the mechanism of sleep. Brain Res 1926;49:257-307.
37. Lhermitte J, Rouques L. Narcolepsie en apparence idiopathique, en réalité sequelle d'encéphalite frustre. Rev Neurol (Paris) 1927;1:751-822.
38. Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001;50:339-348.
39. Melberg A, Dahl N, Hetta J, et al. Neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy. Neurology 1999;53:2190-2192.
40. D'Cruz OF, Vaughn BV, Gold SH, et al. Symptomatic cataplexy in pontomedullary lesions. Neurology 1994;44:2189-2191.
41. Ma TK, Ang LC, Mamelak M, et al. Narcolepsy secondary to fourth ventricular subependymoma. Can J Neurol Sci 1996; 23:59-62.
42. Rivera VM, Meyer JS, Hata T, et al. Narcolepsy following cerebral hypoxic ischemia. Ann Neurol 1986;19:505-508.
43. Guilleminault C, Faull K, Miles L, et al. Post-traumatic daytime sleepiness: a review of 20 patients. Neurology 1983;33:1584-1589.
44. Berg O, Hanley J. Narcolepsy in two cases of multiple sclerosis. Acta Neurol Scand 1963;39:252-257.
45. Schrader H, Gotlibson O. Multiple sclerosis and narcolepsy/cataplexy in a monozygotic twin. Neurology 1980;30:105-108.
46. Younger DS, Pedley TA, Thorpy MJ. Multiple sclerosis and narcolepsy: possible similar genetic susceptibility. Neurology 1991;41:447-448.
47. Autret A, Lucas B, Mondon K, et al. Sleep and brain lesions: a critical review of the literature and additional new cases. Neurophysiol Clin 2001;31:356-375.
48. Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994;35:709-716.
49. Guilleminault C, Mignot E, Grumet FC. Familial patterns of narcolepsy. Lancet 1989;2:1376-1379.
50. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50:S16-S22.
51. Honda Y, Asaka A, Tanimura M, et al. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy or hypersomnia proband. In: Guilleminault C, Lugaresi E, eds. Sleep/wake disorders: natural history, epidemiology, and long-term evolution. New York: Raven Press, 1983:187-199.
52. Neely S, Rosenberg R, Spire JP, et al. HLA antigens in narcolepsy. Neurology 1987;37:1858-1860.
53. Rogers AE, Meehan J, Guilleminault C, et al. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997;48:1550-1556.
54. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001;68:686-699.
55. Mignot E, Young T, Lin L, et al. Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep 1999;22:347-352.
56. Hohjoh H, Terada N, Nakayama T, et al. Case-control study with narcoleptic patients and healthy controls who, like the patients, possess both HLA-DRB1*1501 and -DQB1*0602. Tissue Antigens 2001;57:230-235.
57. Hohjoh H, Nakayama T, Ohashi J, et al. Significant association of a single nudeotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens 1999;54:138-145.
58. Hohjoh H, Terada N, Kawashima M, et al. Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 2000;56:446-448.
59. Hinze-Selch D, Wetter TC, Zhang Y, et al. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 1998;50:1149-1152.
60. Kubota T, Li N, Guan Z, et al. Intrapreoptic microinjection of TNF-alpha enhances non-REM sleep in rats. Brain Res 2002;932:37-44.
61. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001;24:726-731.
62. Jones B. Basic mechanisms of sleep-wake states. In: Kryger M, Roth T, Dement W, eds. Principles and practice of sleep medicine. Philadelphia: WB Saunders, 1994:145-162.
63. Lindsley D, Schreiner L, Knowles W, et al. Behavioral and EEG changes following chronic brain stem lesions in the cat. Electroencephalogr Clin Neurophysiol 1950;2:483.
64. Steriade M, Llinas RR. The functional states of the thalamus and the associated neuronal interplay. Physiol Rev 1988;68:649-742.
65. Steriade M, McCormick DA, Sejnowski TJ. Thalamocortical oscillations in the sleeping and aroused brain. Science 1993; 262:679-685.
66. Kapas L, Obal F Jr, Book AA, et al. The effects of immunolesions of nerve growth factor-receptive neurons by 192 IgG-saporin on sleep. Brain Res 1996;712:53-59.
67. Aston-Jones G, Chiang C, Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res 1991;88:501-520.
68. McGinty D, Harper R. Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res 1976;101:569-575.
69. Vanni-Mercier G, Sakai K, Jouvet M. Specific neurons for wakefulness in the posterior hypothalamus in the cat. C R Acad Sci III 1984;298:195-200.
70. Rye D, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002;58:341-346.
71. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78.
72. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-1794.
73. Trulson ME, Preussler DW. Dopamine-containing ventral tegmental area neurons in freely moving cats: activity during the sleep-waking cycle and effects of stress. Exp Neurol 1984; 83:367-377.
74. Miller JD, Farber J, Gatz P, et al. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and walking in the rat. Brain Res 1983;273:133-141.
75. Jones B, Bobillier P, Pin C, et al. The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res 1973;58:157-177.
76. Sakata M, Sei H, Toida K, et al. Mesolimbic dopaminergic system is involved in diurnal blood pressure regulation. Brain Res 2002;928:194-201.
77. Lu J, Xu M, Saper C. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray (PAG). Sleep 2002;25:A290.
78. McCarley RW, Hobson JA. Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science 1975;189:58-60.
79. Williams JA, Reiner PB. Noradrenaline hyperpolarizes identified rat mesopontine cholinergic neurons in vitro. J Neurosci 1993;13:3878-3883.
80. Leonard CS, Llinas R. Serotonergic and cholinergic inhibition of mesopontine cholinergic neurons controlling REM sleep: an in vitro electrophysiological study. Neuroscience 1994;59:309-330.
81. Steriade M, McCarley RW. Brainstem control of wakefulness and sleep. New York: Plenum, 1990.
82. Lai YY, Shalita T, Hajnik T, et al. Neurotoxic N-methyl-D-aspartate lesion of the ventral midbrain and mesopontine junction alters sleep-wake organization. Neuroscience 1999;90:469-483.
83. Sherin JE, Shiromani PJ, McCarley RW, et al. Activation of ventrolateral preoptic neurons during sleep. Science 1996;271:216-219.
84. Szymusiak R, Alam N, Steininger TL, et al. Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res 1998;803:178-188.
85. Lu J, Greco MA, Shiromani P, et al. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J Neurosci 2000;20:3830-3842.
86. Sherin JE, Elmquist JK, Torrealba F, et al. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 1998;18:4705-4721.
87. Gallopin T, Fort P, Eggermann E, et al. Identification of sleep-promoting neurons in vitro. Nature 2000;404:992-995.
88. Willie JT, Chemelli RM, Sinton CM, et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001;24:429-458.
89. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-585.
90. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-327.
91. Elias CF, Saper CB, Maratos-Flier E, et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998;402:442-459.
92. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015.
93. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-451.
94. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6-25.
95. Estabrooke IV, McCarthy MT, Ko E, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001; 21:1656-1662.
96. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001;14:1075-1081.
97. Alam MN, Gong H, Alam T, et al. Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area. J Physiol 2002;538:619-631.
98. Hagan J, Leslie R, Patel S, et al. Orexin A activates locus coeruleus. cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 1999;96:10911-10916.
99. Bayer L, Eggermann E, Serafin M, et al. Orexins (hypocretins) directly excite tuberomammillary neurons. Eur J Neurosci 2001;14:1571-1575.
100. Yamanaka A, Tsujino N, Funahashi H, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002;290:1237-1245.
101. Eriksson KS, Sergeeva O, Brown RE, et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001;21:9273-9279.
102. Brown RE, Sergeeva O, Eriksson KS, et al. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 2001;40:457-459.
103. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000;20:7760-7765.
104. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001;98:9965-9970.
105. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001;313:125-128.
106. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-376.
107. Tokita S, Chemelli R, Willie J, et al. Behavioral characterization of orexin-2 receptor (OX2R) knockout mice. Sleep 2001; 24:A20-A21.
108. Kisanuki Y, Chemelli R, Tokita S, et al. Behavioral and polysomnographic characterization of orexin-1 receptor and orexin-2 receptor double knockout mice. Sleep 2001;24:A22.
109. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30:345-354.
110. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40.
111. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57:2253-2258.
112. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-388.
113. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002;11:91-93.
114. Dalal MA, Schuld A, Haack M, et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 2001;56:1749-1751.
115. Mignot E, Lammers G, Ripley B, et al. The role of CSF hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-1562.
116. Melberg A, Ripley B, Lin L, et al. Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol 2001;49:136-137.
117. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997.
118. Thannickal T, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474.
119. Olafsdottir BR, Rye DB, Scammell TE, et al. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 2001;57:1896-1899.
120. Hungs M, Lin L, Okun M, et al. Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 2001;57:1893-1895.
121. Matsuki K, Juji T, Honda Y. Immunological features in Japan. In: Honda Y, Juji T, eds. HLA and narcolepsy. New York: Springer Verlag, 1988:58-76.
122. Frey JL, Heiserman JE. Absence of pontine lesions in narcolepsy. Neurology 1997;48:1097-1099.
123. Bassetti C, Aldrich MS, Quint DJ. MRI findings in narcolepsy. Sleep 1997;20:630-631.
124. Han F, Chen E, Wei H, et al. Childhood narcolepsy in North China. Sleep 2001;24:321-324.
125. Kwen PL, Pullicino P. Pontine lesions in idiopathic narcolepsy. Neurology 1998;50:577-578.
126. Rubin RL, Hajdukovich RM, Mitler MM. HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities. Clin Immunol Immunopathol 1988; 49:149-158.
127. Plazzi G, Montagna P, Provini F, et al. Pontine lesions in idiopathic narcolepsy. Neurology 1996;46:1250-1254.
128. Fredrikson S, Carlander B, Billiard M, et al. CSF immune variables in patients with narcolepsy. Acta Neurol Scand 1990; 81:253-254.
129. Erlich SS, Itabashi HH. Narcolepsy: a neuropathologic study. Sleep 1986;9:126-132.
130. Dantz B, Edgar DM, Dement WC. Circadian rhythms in narcolepsy: studies on a 90 minute day. Electroencephalogr Clin Neurophysiol 1994;90:24-35.
131. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci 1995;15:3526-3538.
132. Lavie P. REM periodicity under ultrashort sleep/wake cycle in narcoleptic patients. Can J Psychol 1991;45:185-193.
133. Mayer G, Hellmann F, Leonhard E, et al. Circadian temperature and activity rhythms in unmedicated narcoleptic patients. Pharmacol Biochem Behav 1997;58:395-402.
134. Bourgine N, Claustrat B, Besset A, et al. Melatonin plasma concentration during daytime and nighttime in narcoleptic subjects and controls. Sleep Res 1986;15:46.
135. Weitzman E. Twenty-four hour neuroendocrine secretory patterns: observations on patients with narcolepsy. In: Guilleminault C, Dement W, Passouant P, eds. Narcolepsy. New York: Spectrum, 1976:521-542.
136. Herzog ED, Schwartz WJ. Invited review: a neural clock-work for encoding circadian time. J Appl Physiol 2002;92:401-408.
137. Lu J, Zhang Y, Chou T, et al. Contrasting effects of ibotenate lesions of the paraventricular nucleus and subparaventricular zone on sleep-wake cycle and temperature regulation. J Neurosci 2001;21:4864-4874.
138. Chou T, Scammell T, Lu J, et al. Excitotoxic lesions of the dorsomedial hypothalamic nucleus markedly attenuate circadian rhythms of sleep and body temperature. Paper presented at: Annual Meeting of the Society for Neuroscience; 2000.
139. Gerashchenko D, Kohls MD, Greco M, et al. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J Neurosci 2001;21:7273-7283.
140. Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 1999;96:748-753.
141. Chen CT, Hwang LL, Chang JK, et al. Pressor effects of orexins injected intracisternally and to rostral ventrolateral medulla of anesthetized rats. Am J Physiol Regul Integr Comp Physiol 2000;278:R692-R697.
142. Matsumura K, Tsuchihashi T, Abe I. Central orexin-A augments sympathoadrenal outflow in conscious rabbits. Hypertension 2001;37:1382-1387.
143. Schuld A, Hebebrand J, Geller F, et al. Increased body-mass index in patients with narcolepsy. Lancet 2000;355:1274-1275.
144. Schuld A, Blum WF, Uhr M, et al. Reduced leptin levels in human narcolepsy. Neuroendocrinology 2000;72:195-198.
145. Dahmen N, Bierbrauer J, Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 2001;251:85-89.
146. Lammers GJ, Pijl H, Iestra J, et al. Spontaneous food choice in narcolepsy. Sleep 1996;19:75-76.
147. Furuta H, Thorpy MJ, Temple HM. Comparison in symptoms between aged and younger patients with narcolepsy. Psychiatry Clin Neurosci 2001;55:241-242.
148. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993;16:444-456.
149. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001;24:385-391.
150. Mitler MM, Aldrich MS, Koob GF, et al. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17:352-3571.
151. Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998;1:49-61.
152. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
153. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175.
154. Fry J. A new alternative in the pharmacologic management of somnolence: a phase III study of modafinil in narcolepsy. Ann Neurol 1996;40:493.
155. Mitler M, Harsh J, Hirshkowitz M, et al. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000;1:231-243.
156. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60.
157. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacol (Berl) 1996;126:286-292.
158. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994;17:436-437.
159. Tanganelli S, Fuxe K, Ferraro L, et al. Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 1992; 345:461-465.
160. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 1996;220:5-8.
161. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628.
162. Miller M, Chatterjee S, Aimone L, et al. Novel nondopaminergic wake promoting and cortical activating agents. Paper presented at: Annual Meeting of the Society for Neuroscience; 2001; San Diego.
163. Larrosa O, de la Llave Y, Bario S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001;24:282-285.
164. Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994;44:707-709.
165. Hechler V, Weissmann D, Mach E, et al. Regional distribution of high-affinity gamma-[3H] hydroxybutyrate binding sites as determined by quantitative autoradiography. J Neurochem 1987;49:1025-1032.
166. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB) - a neuroactive drug with abuse potential. J Toxicol Clin Toxicol 1997;35:581-590.
167. Xie X, Smart TG. Gamma-hydroxybutyrate hyperpolarizes hippocampal neurones by activating GABAB receptors. Eur J Pharmacol 1992;212:291-294.
168. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986;9:285-289.
169. Scrima L, Hartman PG, Johnson FH Jr, et al. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990;13:479-490.
170. Lammers GJ, Arends J, Declerck AC, et al. Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993;16:216-220.
171. Cook H, for the US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-49.
172. Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001;344:87-94.
173. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998;31:723-728.
174. Matsuki K, Honda Y, Juji T. Diagnostic criteria for narcolepsy and HLA-DR2 frequencies. Tissue Antigens 1987;30:155-160.
175. Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y, Juji T, eds. HLA in narcolepsy. Berlin: Springer-Verlag, 1988:24-57.
176. Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-1020.
177. Rosenthal LD, Zorick FJ, Merlotti L, et al. Signs and symptoms associated with cataplexy in narcolepsy patients. Biol Psychiatry 1990;27:1057-1060.
178. Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacology 2001; 25:S5-S13.